Vaccine · Immune activation, directed at Streptococcus pneumoniae capsular polysaccharides · developed by Vaxcyte
31 valent pneumococcal conjugate vaccine (VAX-31) is administered by intramuscular injection into the deltoid muscle at a 0.5 mL dose. It is studied for the prevention of pneumococcal disease caused by Streptococcus pneumoniae.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07425392 | Phase 3 | Pneumococcal Vaccines | Active not recruiting | PCVX |
| NCT07284654 | Phase 3 | Pneumococcal Disease | Completed | PCVX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Pneumococcal VaccinesPneumococcal Disease
Updated Oct 25, 2026. Something wrong or missing? Report it on the PCVX page.
See PCVX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PCVX catalysts and pipeline →